- Home
- ABSI
ABSI
Absci Corporation
as 12-24-2024 1:30pm EST
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 457.6M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.45 - $6.72 | Next Earning Date: | 11-12-2024 |
| Revenue: | $4,207,000 | Revenue Growth: | -39.35% |
| Revenue Growth (this year): | 8.57% | Revenue Growth (next year): | 169.72% |
Latest Absci Corporation News
ABSI Breaking Stock News: Dive into ABSI Ticker-Specific Updates for Smart Investing
TipRanks
11 days ago
Absci highlights progress, updates across proprietary pipeline
GlobeNewswire
12 days ago
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
Simply Wall St.
18 days ago
Absci Corporation (NASDAQ:ABSI) is favoured by institutional owners who hold 56% of the company
MT Newswires
20 days ago
JonesTrading Initiates Absci at Buy With $9 Price Target
GlobeNewswire
a month ago
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
GuruFocus.com
a month ago
Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges
Thomson Reuters StreetEvents
a month ago
Q3 2024 Absci Corp Earnings Call
Zacks
a month ago
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
Compare ABSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABSI Absci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.